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Abstract
The pathogenic yeast Candida albicans can develop resistance to the widely used antifungal agent fluconazole, which
inhibits ergosterol biosynthesis, by the overexpression of genes encoding multidrug efflux pumps or ergosterol
biosynthesis enzymes. Zinc cluster transcription factors play a central role in the transcriptional regulation of drug
resistance. Mrr1 regulates the expression of the major facilitator MDR1, Tac1 controls the expression of the ABC transporters
CDR1 and CDR2, and Upc2 regulates ergosterol biosynthesis (ERG) genes. Gain-of-function mutations in these transcription
factors result in constitutive overexpression of their target genes and are responsible for fluconazole resistance in many
clinical C. albicans isolates. The transcription factor Ndt80 contributes to the drug-induced upregulation of CDR1 and ERG
genes and also binds to the MDR1 and CDR2 promoters, suggesting that it is an important component of all major
transcriptional mechanisms of fluconazole resistance. However, we found that Ndt80 is not required for the induction of
MDR1 and CDR2 expression by inducing chemicals. CDR2 was even partially derepressed in ndt80D mutants, indicating that
Ndt80 is a repressor of CDR2 expression. Hyperactive forms of Mrr1, Tac1, and Upc2 promoted overexpression of MDR1,
CDR1/CDR2, and ERG11, respectively, with the same efficiency in the presence and absence of Ndt80. Mrr1- and Tac1-
mediated fluconazole resistance was even slightly enhanced in ndt80D mutants compared to wild-type cells. These results
demonstrate that Ndt80 is dispensable for the constitutive overexpression of Mrr1, Tac1, and Upc2 target genes and the
increased fluconazole resistance of strains that have acquired activating mutations in these transcription factors.
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Introduction
Infections by the pathogenic yeast Candida albicans are commonly
treated with the antifungal agent fluconazole, which blocks ergosterol
biosynthesis by inhibiting sterol 14a-demethylase, a key enzyme in
the ergosterol biosynthetic pathway. C. albicans can develop resistance
to fluconazole by various mechanisms, including mutations in the
target enzyme that decrease its affinity to the drug, increased
expression of the ERG11 gene encoding sterol 14a-demethylase, or
overexpression of multidrug efflux pumps of the ABC transporter and
major facilitator superfamilies [1]. Many details of the molecular basis
of drug resistance in C. albicans have been elucidated in recent years,
especially with the identification of transcription factors that regulate
the expression of ergosterol biosynthesis genes and multidrug efflux
pumps. Transcription factors of the zinc cluster family, which is
specific for fungi, have central roles in the transcriptional control of
fluconazole resistance in C. albicans. Upc2 regulates the expression of
ERG11 and other ERG genes [2,3], Tac1 controls the expression of
the ABC transporters CDR1 and CDR2 [4], and Mrr1 regulates the
expression of the major facilitator MDR1 [5]. Mutants lacking these
transcription factors cannot upregulate their target genes in response
to inducing stimuli. In addition, fluconazole-resistant, clinical C.
albicans isolates that overexpress CDR1 and CDR2, MDR1, or ERG11
contain gain-of-function mutations in Tac1, Mrr1, and Upc2,
respectively, which render the transcription factors constitutively
active even under noninducing conditions and are responsible for the
increased drug resistance of these strains [4,5,6,7,8,9,10,11,12,13,14].
While Mrr1, Tac1, and Upc2 each contribute in different and
specific ways to the development of fluconazole resistance, another
transcription factor, Ndt80, seems to be involved in the
transcriptional regulation of Mrr1, Tac1, and Upc2 target genes
and therefore have a much broader role in fluconazole resistance
and many other cellular functions in C. albicans [15,16]. NDT80
was originally identified as a gene that increased CDR1 promoter
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activity when it was overexpressed from a multicopy plasmid in the
heterologous host Saccharomyces cerevisiae [17]. Deletion of NDT80 in
C. albicans resulted in reduced basal CDR1 expression levels, and
induction of CDR1 expression by miconazole was abolished in the
ndt80D mutants, which became hypersusceptible to fluconazole and
voriconazole [17,18]. Expression of NDT80 itself was found to be
induced upon treatment of C. albicans cells with itraconazole or
miconazole [17,19]. The involvement of Ndt80 in CDR1 regulation
was corroborated by the finding that Ndt80 binds to the CDR1
promoter in vivo [16]. Interestingly, Ndt80 also binds to the
promoters of the efflux pumps CDR2 and MDR1 and those of genes
encoding ergosterol biosynthesis enzymes, including ERG11 [16].
Ndt80 therefore seems to be involved in the transcriptional
regulation of all major mechanisms of azole resistance in C. albicans.
While a role of Ndt80 in CDR1 expression and fluconazole-
induced upregulation of ERG genes has been demonstrated
[16,17], the relevance of Ndt80 binding to the promoters of
MDR1 and CDR2 for the expression of these efflux pumps has not
yet been addressed. We therefore investigated if Ndt80 is required
for MDR1 and CDR2 upregulation by chemicals that are known to
induce the expression of these drug transporters. In addition, we
studied the importance of Ndt80 for the constitutive overexpres-
sion of MDR1, CDR1/CDR2, and ERG11 in strains containing
hyperactive MRR1, TAC1, and UPC2 alleles, respectively, which
confer increased fluconazole resistance in clinical C. albicans
isolates.
Results
Role of Ndt80 in MDR1 induction and constitutive MDR1
overexpression
To evaluate the importance of Ndt80 for MDR1 expression, we
constructed two independent ndt80D mutants of the wild-type
strain SC5314 by the SAT1 flipping method (see Materials and
methods). We then integrated the GFP reporter gene under the
control of the native MDR1 promoter in the wild type and the
ndt80D mutants to quantify MDR1 promoter activity. For
comparison, the reporter fusion was also introduced in two
independently generated mrr1D mutants of strain SC5314. The
MDR1 gene is not significantly expressed under standard growth
conditions, but it is activated in the presence of benomyl [5,20,21].
FACS analysis of the cells showed that Ndt80 was not required for
the induction of the MDR1 promoter by benomyl, whereas MDR1
induction was abolished in cells lacking Mrr1 (Figure 1A). As the
ndt80D mutants displayed a higher background fluorescence than
the wild type, we also detected GFP expression by Western
immunoblotting (Figure 1B). These experiments confirmed that
comparable amounts of GFP were produced in the presence and
absence of NDT80, i.e., Ndt80 was dispensable for the induction of
the MDR1 promoter by benomyl.
A more important question with respect to drug resistance was
whether Ndt80 contributes to the constitutive MDR1 overexpres-
sion in strains containing a hyperactive Mrr1. To address this
issue, we introduced a gain-of-function mutation that causes a
P683S amino acid substitution into both endogenous MRR1 alleles
of the wild-type strain SC5314 and the ndt80D mutants. The
PMDR1-GFP reporter fusion was then integrated into these strains
to compare their MDR1 promoter activities. FACS and Western
immunoblot analysis of GFP expression demonstrated that the
hyperactive Mrr1 induced the MDR1 promoter with similar
efficiency in both strain backgrounds (Figure 2A and B).
To evaluate the phenotypic consequences of expression of a
hyperactive Mrr1 in the absence of Ndt80, we determined the
fluconazole susceptibilities of wild-type and ndt80D strains
containing native or hyperactive MRR1 alleles (Figure 2C). In
line with previous results [22], expression of the hyperactive
MRR1P683S allele in the wild-type background resulted in a 16-fold
increase in fluconazole resistance (MIC increased from 0.39 to
6.25 mg/ml). In accord with findings by other researchers [16,17],
we observed an enhanced fluconazole sensitivity of the ndt80D
mutants. Surprisingly, however, the presence of the hyperactive
MRR1P683S allele caused an even stronger increase in fluconazole
resistance in the ndt80D mutants (MIC increased from 0.2 to
12.5 mg/ml) than in their wild-type parent. To confirm that this
phenotype was indeed caused by the deletion of NDT80, we
reinserted a functional NDT80 copy into the homozygous ndt80D
mutants. The reintroduction of NDT80 reverted the fluconazole
susceptibilities of the ndt80D mutants expressing native of
hyperactive MRR1 alleles to the levels observed in the corre-
sponding wild-type strains.
Altogether, these results demonstrated that Ndt80 is dispensable
for MDR1 upregulation in response to the inducer benomyl and
for the constitutive MDR1 overexpression caused by a hyperactive
Mrr1. In addition, Ndt80 has a negative effect on Mrr1-mediated
fluconazole resistance, presumably by reducing the expression of
other Mrr1 target genes that also contribute to drug resistance
[22].
Figure 1. Inducibility of theMDR1 promoter in wild-type,mrr1D,
and ndt80D strains. (A) Strains carrying a PMDR1-GFP reporter fusion in
the indicated genetic backgrounds were grown in the absence (2) or
presence (+) of benomyl as described in Materials and methods. The
mean fluorescence of the cells was determined by flow cytometry. The
results obtained with two independently generated reporter strains are
shown in each case (means and standard deviations from three
experiments). The following strains were used (see Table S1): SCMG3A
and -B (wild type), SCDmrr1MG3A and -B (mrr1D), SCDndt80MG3A and
-B (ndt80D). The background fluorescence of the parental strains, which
do not contain the GFP gene, is indicated by the black part in each
column. (B) GFP expression in the same strains was detected by
Western immunoblotting with an anti-GFP antibody. The two blots
show the results with the A and B series of strains.
doi:10.1371/journal.pone.0025623.g001
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Role of Ndt80 in CDR2 induction and constitutive CDR2
overexpression
As explained in the introduction, Ndt80 also binds to the
promoter of the ABC transporter CDR2, which like CDR1 is
regulated by the zinc cluster transcription factor Tac1. CDR2 is
not significantly expressed under standard growth conditions, but
its expression is strongly induced by fluphenazine [21,23,24]. To
investigate if Ndt80 is required for the activation of the CDR2
promoter in response to this compound, we integrated a PCDR2-
GFP reporter fusion into the endogenous CDR2 locus of the wild-
type strain SC5314 and the ndt80D mutants. For comparison, the
reporter fusion was also introduced in two independently
generated tac1D mutants of strain SC5314. FACS analysis of the
cells (Figure 3A) and Western immunoblot analysis of GFP
expression (Figure 3B) demonstrated that the CDR2 promoter was
efficiently induced by fluphenazine in both the wild type and the
ndt80D mutants, while no induction was observed in tac1D
mutants, in agreement with previous findings [4]. Interestingly,
the ndt80D mutants also exhibited a basal CDR2 promoter activity
in the absence of the inducer, in contrast to the wild type, in which
no CDR2 expression was detectable under noninducing conditions.
These results indicated that Ndt80 is a repressor of CDR2
expression.
Activating mutations in Tac1 result in constitutive CDR2
overexpression in fluconazole-resistant strains. To investigate
whether Ndt80 affects CDR2 induction by a hyperactive Tac1,
we introduced a gain-of-function mutation that results in a G980E
amino acid substitution into both endogenous TAC1 alleles of the
wild-type strain SC5314 and the ndt80D mutants. The PCDR2-GFP
reporter fusion was then integrated into these strains to compare
their CDR2 promoter activities. FACS analysis of the cells
(Figure 4A) and Western immunoblot analysis of GFP expression
(Figure 4B) demonstrated that the hyperactive Tac1 induced the
CDR2 promoter in the ndt80D mutants with similar efficiency as in
wild-type cells.
In order to determine if a hyperactive Tac1 can mediate
increased drug resistance in ndt80D mutants, we compared the
fluconazole susceptibilities of wild-type and ndt80D strains
containing native or hyperactive TAC1 alleles (Figure 4C). In the
wild-type background, the TAC1G980E allele caused an 8-fold
increased fluconazole resistance (MIC increased from 0.39 to
3.13 mg/ml). An even stronger increase in resistance (32-fold) was
observed in the ndt80D mutants, in which the MIC rose from 0.2
to 6.25 mg/ml. When a single NDT80 copy was reinserted into the
homozygous ndt80D mutants containing the TAC1G980E alleles, the
MIC of fluconazole remained at 6.25 mg/ml, but the strains
showed reduced growth at 3.13 mg/ml, indicating that their
resistance was intermediate between that of cells containing two
NDT80 copies or none. These results demonstrated that Ndt80
also has a negative effect on Tac1-mediated fluconazole resistance.
Ndt80 is not required for Tac1-mediated CDR1
overexpression
CDR1 and CDR2 are usually coregulated by Tac1 [4,6,7,14]. In
the light of previous reports that Ndt80 is an activator of CDR1
expression [17,18], our findings that NDT80 is not required for the
inducible or constitutive upregulation of CDR2 and even inhibits
CDR2 expression under noninducing conditions therefore came as
a surprise. As CDR1 makes a stronger contribution than CDR2 to
the increased drug resistance of strains in which these ABC
transporters are overexpressed [25,26], we compared the CDR1
promoter activities of strains containing native or hyperactive
TAC1 alleles in wild-type and ndt80D backgrounds. As can be seen
Figure 2. MDR1 promoter activity and fluconazole resistance of
strains expressing the hyperactiveMRR1P683S allele in wild-type
and ndt80D backgrounds. (A) Reporter strains containing wild-type
or hyperactiveMRR1 alleles and expressing GFP under the control of the
MDR1 promoter were grown to log phase in YPD medium. The mean
fluorescence of the cells was determined by flow cytometry. The results
obtained with two independently generated reporter strains are shown
in each case (means and standard deviations from three experiments).
The following strains were used (see Table S1): SCMG3A and -B (wild
type, MRR1), SCMRR1R34MG3A and -B (wild type, MRR1P683S),
SCDndt80MG3A and -B (ndt80D, MRR1), SCDndt80MRR1R34MG3A and
-B (ndt80D, MRR1P683S). The background fluorescence of the parental
strains, which do not contain the GFP gene, is indicated by the black
part in each column. (B) GFP expression in the same strains was
detected by Western immunoblotting with an anti-GFP antibody. (C)
MIC of fluconazole for strains containing wild-type MRR1 or MRR1P683S
alleles in the indicated genetic backgrounds. *, reduced growth was
already observed at 6.25 mg/ml fluconazole.
doi:10.1371/journal.pone.0025623.g002
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in Figure 5, the hyperactive Tac1 caused a similar constitutive
CDR1 overexpression in the presence and absence of Ndt80,
explaining our finding that Ndt80 is not required for Tac1-
mediated fluconazole resistance.
Ndt80 is dispensable for ERG11 upregulation by a
hyperactive Upc2
Ndt80 has been found to contribute to the fluconazole-induced
upregulation of ergosterol biosynthesis genes, including ERG11
[16]. Gain-of-function mutations in the zinc cluster transcription
factor Upc2 result in constitutive ERG11 overexpression and
increased fluconazole resistance [10,11,12]. To evaluate the
importance of Ndt80 for the Upc2-mediated constitutive ERG11
upregulation, we introduced a gain-of-function mutation that
results in a G648D amino acid substitution into both endogenous
UPC2 alleles of the wild-type strain SC5314 and the ndt80D
mutants. The PERG11-GFP reporter fusion was then integrated into
these strains to compare their ERG11 promoter activities. FACS
analysis of the cells (Figure 6A) and Western immunoblot analysis
of GFP expression (Figure 6B) demonstrated that the hyperactive
Upc2 caused a constitutive ERG11 overexpression in the presence
and absence of Ndt80. To assess whether the hyperactive Upc2
could mediate increased fluconazole resistance in ndt80D mutants,
we determined the MIC of fluconazole for the strains. Expression
of the hyperactive Upc2 resulted in a 4-fold increase in fluconazole
resistance in both the wild type and the ndt80D mutants, although
the hypersusceptibility of the ndt80D mutants as compared with
the wild type was conserved in the presence of the UPC2G648D
allele (Figure 6C). Reintroduction of a single copy of NDT80 in the
ndt80D mutants restored fluconazole resistance to the level of the
corresponding wild-type strains. These results demonstrate that
Ndt80 is not required for the constitutive ERG11 overexpression
and the resulting increase in fluconazole resistance caused by a
hyperactive Upc2.
Discussion
Previous findings that Ndt80 contributes to the drug-induced
upregulation of CDR1 and ERG11 and that it also binds to the
promoters of MDR1 and CDR2 suggested that Ndt80 is involved in
all major transcriptional mechanisms of fluconazole resistance in
C. albicans [16,17]. We found that Ndt80 was dispensable for the
upregulation of MDR1 in response to the inducer benomyl and for
the induction of CDR2 expression by fluphenazine. In fact, CDR2
expression was partially derepressed in ndt80D mutants, arguing
that Ndt80 binds to the CDR2 promoter to act as a repressor of
this efflux pump under noninducing conditions. In contrast to
a previous report [17], we did not observe a reduced basal
expression of CDR1 in the absence of Ndt80 (Figure 5). However,
this result concurs with another study in which CDR1 was not
found among the genes that were differentially expressed in an
ndt80D mutant [16].
It is likely that Ndt80 is required only under specific conditions
for the expression of the genes to which it binds. Ndt80 was shown
to bind to the promoter regions of 23% of C. albicans genes, but the
expression of many of these genes was not altered after deletion of
NDT80 under the conditions tested [16]. Similarly, the zinc cluster
transcription factor Upc2, which regulates the expression of
ergosterol biosynthesis genes, also binds to the MDR1 promoter,
but it is required neither for the benomyl-induced upregulation of
the efflux pump nor for its constitutive upregulation by a
hyperactive Mrr1 [22]. Nevertheless, under certain environmental
conditions Upc2 can act either as an activator or a repressor of
MDR1 expression [27]. Ndt80 may therefore also modulate MDR1
and CDR2 expression levels under other conditions than those
used in our present study.
Apart from the role of Ndt80 in modulating gene expression in
response to environmental signals, which may vary depending on
the conditions, a more important question with respect to drug
resistance was whether Ndt80 is required for the constitutive
overexpression of genes mediating azole resistance in strains that
have acquired activating mutations in the transcription factors
Mrr1, Tac1, or Upc2. To address this issue, we compared the
promoter activities of relevant target genes in strains expressing
activated forms of the transcription factors in the presence and
absence of Ndt80. Our results demonstrate that Ndt80 is not
required for the constitutive overexpression of MDR1, CDR1/
CDR2, and ERG11 and the resulting increase in fluconazole
resistance caused by hyperactive Mrr1, Tac1, and Upc2,
respectively. In fact, strains expressing hyperactive Mrr1 or Tac1
even displayed somewhat higher fluconazole resistance in the
absence of Ndt80 than in its presence. Besides the efflux pumps,
additional genes are upregulated in strains containing gain-of-
function mutations in Mrr1 or Tac1, and these genes also
contribute to the increased drug resistance of such strains [22,28].
Apparently, the overexpression of Mrr1 and Tac1 target genes
overcomes defects of the ndt80D mutants which are responsible for
Figure 3. Inducibility of the CDR2 promoter in wild-type, tac1D,
and ndt80D strains. (A) Strains carrying a PCDR2-GFP reporter fusion in
the indicated genetic backgrounds were grown in the absence (2) or
presence (+) of fluphenazine as described in Materials and methods.
The mean fluorescence of the cells was determined by flow cytometry.
The results obtained with two independently generated reporter strains
are shown in each case (means and standard deviations from three
experiments). The following strains were used (see Table S1): SCCG3A
and -B (wild type), SCDtac1CG3A and -B (tac1D), SCDndt80CG3A and -B
(ndt80D). The background fluorescence of the parental strains, which do
not contain the GFP gene, is indicated by the black part in each column.
(B) GFP expression in the same strains was detected by Western
immunoblotting with an anti-GFP antibody. The two blots show the
results with the A and B series of strains.
doi:10.1371/journal.pone.0025623.g003
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their fluconazole hypersusceptibility, and the absence of Ndt80
augments the capacity of constitutively active Mrr1 and Tac1 to
mediate fluconazole resistance.
Our finding that Ndt80 is dispensable for the constitutive
overexpression of MDR1, CDR1/CDR2, and ERG11 in strains with
gain-of-function mutations in the zinc cluster transcription factors
Mrr1, Tac1, and Upc2, respectively, also has potential practical
implications. Combating drug resistance is an important goal to
maintain the efficiency of currently used antifungal drugs, which
could be achieved by inhibiting efflux pumps or their transcrip-
tional regulators [29,30]. As Mdr1 and Cdr1/Cdr2 belong to
different classes of transporters, their activities probably cannot be
blocked by the same inhibitor. Similarly, the two types of efflux
pumps and the ergosterol biosynthesis genes are specifically
regulated by distinct zinc cluster transcription factors. A common
mechanism that is used by Mrr1, Tac1, and Upc2 could provide a
target for the simultaneous inhibition of several transcriptional
mechanisms of drug resistance. As Ndt80 binds to the promoters
of the major azole resistance genes and, at least under some
conditions, contributes to the azole-induced expression of CDR1
and ergosterol biosynthesis genes, it seemed to be an attractive
candidate for such an approach. However, as we have shown in
this study, hyperactive forms of Mrr1, Tac1, and Upc2, which are
often the cause of azole resistance in clinical C. albicans isolates, do
not require Ndt80 to upregulate their target genes and thereby
mediate drug resistance. Therefore, blocking Ndt80 would be of
little use in attempts to override the azole resistance of clinical
strains.
Materials and Methods
Strains and growth conditions
The C. albicans strains used in this study are listed in Table S1.
All strains were stored as frozen stocks with 15% glycerol at
280uC and subcultured on YPD agar plates (10 g yeast extract,
20 g peptone, 20 g glucose, 15 g agar per liter) at 30uC. Strains
were routinely grown in YPD liquid medium at 30uC in a
shaking incubator. For selection of nourseothricin-resistant
transformants, 200 mg/ml nourseothricin (Werner Bioagents,
Jena, Germany) was added to YPD agar plates. To obtain
nourseothricin-sensitive derivatives in which the SAT1 flipper
cassette was excised by FLP-mediated recombination, transfor-
mants containing the NDT80 deletion cassette were grown
overnight in YCB-BSA-YE medium (23.4 g yeast carbon base,
4 g bovine serum albumin, 2 g yeast extract per liter, pH 4.0)
without selective pressure to induce the SAP2 promoter
controlling caFLP expression. Alternatively, strains containing
a SAT1 flipper cassette in which the caFLP gene is expressed
from the MAL2 promoter (as in plasmids pTAC1M1,
pMRR1R3, pTAC1R3, and pUPC2R1) were grown overnight
in YPM medium (10 g yeast extract, 20 g peptone, 20 g maltose
per liter) instead of YCB-BSA-YE to induce the MAL2
promoter. One hundred to 200 cells were then spread on
YPD plates containing 10 mg/ml nourseothricin and grown for
2 days at 30uC. Nourseothricin-sensitive clones were identified
by their small colony size and confirmed by restreaking on
YPD plates containing 200 mg/ml nourseothricin as described
previously [31]. For the induction of the MDR1 and CDR2
promoters, overnight cultures of the GFP reporter and parental
strains were diluted 1022 in 3 ml fresh YPD medium in glass
tubes and grown for 3 h at 30uC. After adding 50 mg/ml
benomyl or 10 mg/ml fluphenazine, the cultures were incubated
for an additional hour and the fluorescence of the cells was
quantified by fluorescence-activated cell sorter (FACS) analysis.
For the detection of GFP by Western immunoblotting, cells
Figure 4. CDR2 promoter activity and fluconazole resistance of strains expressing the hyperactive TAC1G980E allele in wild-type and
ndt80D backgrounds. (A) Reporter strains containing wild-type or hyperactive TAC1 alleles and expressing GFP under the control of the CDR2
promoter were grown to log phase in YPD medium. The mean fluorescence of the cells was determined by flow cytometry. The results obtained with
two independently generated reporter strains are shown in each case (means and standard deviations from three experiments). The following strains
were used (see Table S1): SCCG3A and -B (wild type, TAC1), SCTAC1R34CG3A and -B (wild type, TAC1G980E), SCDndt80CG3A and -B (ndt80D, TAC1),
SCDndt80TAC1R34CG3A and -B (ndt80D, TAC1G980E). The background fluorescence of the parental strains, which do not contain the GFP gene, is
indicated by the black part in each column. (B) GFP expression in the same strains was detected by Western immunoblotting with an anti-GFP
antibody. (C) MIC of fluconazole for strains containing wild-type TAC1 or TAC1G980E alleles in the indicated genetic backgrounds. *, reduced growth
was already observed at 3.13 mg/ml fluconazole.
doi:10.1371/journal.pone.0025623.g004
Figure 5. CDR1 promoter activity in strains expressing the
hyperactive TAC1G980E allele in wild-type and ndt80D back-
grounds. (A) Reporter strains containing wild-type or hyperactive TAC1
alleles and expressing GFP under the control of the CDR1 promoter
were grown to log phase in YPD medium. The mean fluorescence of the
cells was determined by flow cytometry. The results obtained with two
independently generated reporter strains are shown in each case
(means and standard deviations from three experiments). The following
strains were used (see Table S1): SCCG1A and -B (wild type, TAC1),
SCTAC1R34CG1A and -B (wild type, TAC1G980E), SCDndt80CG1A and -B
(ndt80D, TAC1), SCDndt80TAC1R34CG1A and -B (ndt80D, TAC1G980E). The
background fluorescence of the parental strains, which do not contain
the GFP gene, is indicated by the black part in each column. (B) GFP
expression in the same strains was detected by Western immunoblot-
ting with an anti-GFP antibody.
doi:10.1371/journal.pone.0025623.g005
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were treated as described above, except that the cultures were
grown in 50 ml volumes in Erlenmeyer flasks to obtain sufficient
amounts of cells.
Plasmid constructions
For the deletion of NDT80, we first generated a modified
SAT1 flipper cassette in which the MAL2 promoter controlling
caFLP expression was replaced by a 4 kb fragment containing
the promoter of the SAP2-1 allele of strain SC5314 [32]. For
this purpose, a SalI site in the caSAT1 marker of pSFS2 [31]
was first removed by inserting an XhoI-PstI fragment
containing the caSAT1 marker from pNIM6 [33] instead of
the corresponding SalI-PstI fragment in pSFS2, resulting in
pSFS4. The SAP2-1 upstream region was then amplified from
genomic DNA of strain SC5314 with the primers SAP2P27
and IPCR1 (all primers used in this study are listed in Table
S2). The PCR product was digested at the introduced BamHI
and SalI sites and used to replace the MAL2 promoter in
pSFS4, thereby generating pSFS5. In contrast to previous
versions of the SAT1 flipper cassette, in which caFLP expression
is driven from the leaky MAL2 promoter or a shorter SAP2
promoter fragment, caFLP expression is tightly controlled and
efficiently inducible after integration of the modified SAT1
flipper cassette from pSFS5 into the C. albicans genome. The
NDT80 upstream and downstream regions were amplified with
the primer pairs NDT80-4/NDT80-5 and NDT80-6/NDT80-
7, respectively, and the SacI/SacII- and XhoI/ApaI-digested
PCR products were cloned on both sides of the SAT1 flipper
cassette of pSFS5 to generate pNDT80M3. For reintroduction
of NDT80 into ndt80D mutants, the NDT80 coding region and
ca. 0.5 kb of upstream and downstream sequences were
amplified with the primers NDT80-4 and NDT80-compl.
The PCR product was digested with SacI and SacII and used
to replace the NDT80 upstream region in pNDT80M3,
resulting in pNDT80K1.
Plasmid pERG11G2 contains a Candida-adapted GFP reporter
gene [34] under the control of the ERG11 promoter [11]. Similar
plasmids in which GFP expression is driven by the MDR1, CDR1,
and CDR2 promoters were constructed by substituting the
upstream and downstream regions of the corresponding genes
for the ERG11 flanking sequences in pERG11G2, resulting in
plasmids pMDR1G3, pCDR1G1, and pCDR2G3, respectively.
The MDR1 upstream and downstream regions were amplified
with the primer pairs MDR1p5/MDR1p7 and MDR1-3/
MDR1-4, the CDR1 upstream and downstream regions were
amplified with the primer pairs CDR1F/CDR1R and CDR29/
CDR30, and the CDR2 upstream and downstream regions were
amplified with the primer pairs CDR2-5/CDR2-6 and CDR2-3/
CDR2-4.
Plasmids pUPC2R1 and pMRR1R3, which were used to
replace the UPC2 and MRR1 wild-type alleles by the UPC2G648D
and MRR1P683S alleles, respectively, with the help of the SAT1
flipper cassette, were described previously [11,22]. To obtain an
analogous cassette for introduction of the TAC1G980E allele, the
TAC1 downstream region was first amplified with the primers
TAC1-6 and TAC1-7, and the XhoI/ApaI-digested PCR
product was substituted for the UPC2 downstream fragment
in pUPC2R1, yielding pTAC1R1. The C-terminal part of the
TAC1 gene was then amplified with the primers TAC1-11
and TAC1hyp-2, thereby introducing a G2939A exchange that
results in the G980E gain-of-function mutation in Tac1 [6]. The
PCR product was digested with SacI/BamHI and substituted for
the UPC2G648D allele in the SacI/BglII-digested pTAC1R1 to
obtain pTAC1R3. A TAC1 deletion cassette was generated by
amplifying the TAC1 upstream region with the primers TAC1-14
and TAC1-15 and substituting the SacI/SacII-digested PCR
product for the UPC2 sequences in pTAC1R1 to obtain
pTAC1M1.
Figure 6. ERG11 promoter activity and fluconazole resistance of
strains expressing the hyperactive UPC2G648D allele in wild-
type and ndt80D backgrounds. (A) Reporter strains containing wild-
type or hyperactive UPC2 alleles and expressing GFP under the control
of the ERG11 promoter were grown to log phase in YPD medium. The
mean fluorescence of the cells was determined by flow cytometry. The
results obtained with two independently generated reporter strains are
shown in each case (means and standard deviations from three
experiments). The following strains were used (see Table S1): SCEG2A
and -B (wild type, UPC2), SCUPC2R14CG2A and -B (wild type,
UPC2G648D), SCDndt80EG2A and -B (ndt80D, UPC2) SCDndt80UP-
C2R14EG2A and -B (ndt80D, UPC2G648D). The background fluorescence
of the parental strains, which do not contain the GFP gene, is indicated
by the black part in each column. (B) GFP expression in the same strains
was detected by Western immunoblotting with an anti-GFP antibody.
(C) MIC of fluconazole for strains containing wild-type UPC2 or
UPC2G648D alleles in the indicated genetic backgrounds.
doi:10.1371/journal.pone.0025623.g006
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Strain constructions
C. albicans strains were transformed by electroporation [35] with
the following gel-purified linear DNA fragments: the SacI-ApaI
fragments from pNDT80M3 and pTAC1M1 were used to delete
the NDT80 and TAC1 genes, respectively, in strain SC5314. The
SacI-ApaI fragment from pNDT80K1 was used to reintroduce a
functional NDT80 copy into ndt80D mutants. The SacI-ApaI
fragments from pMRR1R3, pTAC1R3, and pUPC2R1 were used
to introduce the hyperactive MRR1P683S, TAC1G980E, and
UPC2G648D alleles, respectively, instead of the corresponding wild-
type alleles in strain SC5314 and in the ndt80D mutants. The ApaI-
SacI fragment from pERG11G2, the ApaI-SacII fragment from
pCDR1G1, the KpnI-SacII fragment from pCDR2G3, and the
XhoI-SacII fragment from pMDR1G3 were used to integrate the
PERG11-GFP, PCDR1-GFP, PCDR2-GFP, and PMDR1-GFP reporter
fusions into the corresponding genomic loci in different strains (see
Table S1). The correct integration of each construct was confirmed
by Southern hybridization with gene-specific probes. The intro-
duction of the P683S, G980E, and G648D mutations into the first
and second alleles of MRR1, TAC1, and UPC2, respectively, of the
transformants was confirmed by reamplification with specific
primers and direct sequencing of the PCR products.
Isolation of genomic DNA and Southern hybridization
Genomic DNA from C. albicans strains was isolated as described
previously [31]. The DNA was digested with appropriate
restriction enzymes, separated on a 1% agarose gel and, after
ethidium bromide staining, transferred by vacuum blotting onto
a nylon membrane and fixed by UV crosslinking. Southern
hybridization with enhanced chemiluminescence-labeled probes
was performed with the Amersham ECLTM Direct Nucleic Acid
Labelling and Detection System (GE Healthcare UK Limited,
Little Chalfont Buckinghamshire, UK) according to the instruc-
tions of the manufacturer.
FACS analysis
Fluorescence-activated cell sorter (FACS) analysis was per-
formed with a FACSCalibur cytometry system equipped with an
argon laser emitting at 488 nm (Becton Dickinson, Heidelberg,
Germany). Fluorescence was measured on the FL1 fluorescence
channel equipped with a 530-nm band-pass filter. Twenty
thousand cells were analyzed per sample and were counted at a
flow rate of 500 cells per second. Fluorescence data were collected
by using logarithmic amplifiers. The mean fluorescence (arbitrary
values) was determined with CellQuest Pro (Becton Dickinson)
software.
Western immunoblotting
Cells were collected by centrifugation, washed in 2.5 ml
breaking buffer (100 mM Tris-HCl [pH 7.5], 200 mM NaCl,
20% glycerol, 5 mM EDTA), and broken by vortexing for 10 min
at 4uC with 500 ml 0.5 mm glass beads in 500 ml breaking buffer
(100 mM Tris-HCl [pH 7.5], 200 mM NaCl, 20% glycerol,
5 mM EDTA, 4% Complete, EDTA-free Protease Inhibitor
Cocktail [Roche Diagnostics GmbH, Mannheim, Germany], 0.1%
b-mercaptoethanol). Samples were centrifuged at 13,000 rpm for
10 min at 4uC, the supernatant was collected, and the protein
concentration was quantified using the Bradford protein assay.
Extracts were heated for 10 min at 65uC, and equal amounts of
protein of each sample were separated on an SDS-12% polyacryl-
amide gel. Proteins were transferred onto a nitrocellulose
membrane with a Mini-Protean Tetra System (Bio-Rad, Munich,
Germany) and stained with Ponceau S to control for equal loading.
GFP was detected using rabbit monoclonal GFP antibody ab32146
(Abcam, Cambridge, UK) and anti rabbit HRP G-21234 (Invitro-
gen GmbH, Darmstadt, Germany) as first and secondary
antibodies, respectively. A chemiluminescence detection system
(GE Healthcare) was used for signal detection.
Fluconazole susceptibility assays
The fluconazole susceptibilities of the strains were determined
using a previously described microdilution method [36], except
that the assay was performed in SD medium (6.7 g yeast nitrogen
base without amino acids [YNB; BIO 101, Vista, Calif.], 20 g
glucose, 0.77 g of complete supplement medium [CSM, BIO101]),
because HR medium, which we used in previous studies, was not
commercially available any more. Both media produced largely
identical results.
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